
ABPI appoints former AZ innovation head
pharmafile | June 17, 2010 | Appointment | Research and Development, Sales and Marketing | ABPI, appointment, research and development, sales and marketing
UK industry association the ABPI has appointed Carol Blount as its new head of commercial affairs.
Carol has more than 15 years’ senior leadership experience within UK pharma, most recently as head of innovation for AstraZeneca where she led a number of initiatives including joint working projects with industry and PCTs
Prior to this she worked for Bayer and her experience includes leadership of strategic innovation and change, business development and brand marketing leading to increased sales and contribution
“With a new Government and an uncertain financial situation throughout the world, these are challenging times for our industry,” said Carol. “I am very much looking forward to working in my new role to help tackle some of the vitally important issues facing the industry.”
In her new role, she will be responsible for managing all commercial affairs and initiatives within the ABPI, including NHS Joint Working and quality, innovation, prevention and productivity (QIPP) initiatives, delivery of commercial aspects of the PPRS, supply chain and distribution initiatives.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






